442 results about "Thymus Glands" patented technology

Provided are compounds represented by: X is O, S or NR6, R1 is H or (CH2)mR5, R2, R2', R3 and R3' are independently NO2, N3 or (CH2)mR5, OH R4 is H, OR6, SR6, NR6R6a, CN, C(O)OR6, C(O)NR6R6a, R6, OR7 or (CH2)nR7, R5 is H, halo, OR6, SR6, NR6R6a, CN, C(O)OR6, C(O)NR6R6a, R6, OR7 or (CH2)mR7, R6 and R6a are individually H, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, aryl or substituted aryl, R7 is: R8 is H, F, SR9 or OR9, R9 is H, alkyl, alkenyl, alkynyl, aryl or hydroxyprotecting group, Y is H, CH3 or (CH2)mR5, Z is O or S W is CH2, CF2, CHF or O, m is 0-4, B is adenine, guanine, cytosine, uracil, thymine, modified purines and pyrimidines substituted pyridines, five membered heterocycles substituted by at least one of amines, substituted amines, amides, substituted amides, esters, halogens, alkyls, ethers; and pharmaceutically acceptable salts thereof and prodrugs thereof. These ring systems may be substituted.

A cell surface molecule that is expressed specifically in thymocytes, lymphocytes activated by ConA-stimulation, and peripheral blood lymphocytes. This molecule is involved in signal transmission of the secondary signal (costimulatory signal) essential for the activation of lymphocytes such as T cells and regulates functions of activated lymphocytes such as activated T cells. Disclosed are an antibody or a portion thereof, which binds to a polypeptide of the cell surface molecule, a polypeptide fragment thereof, or a fusion polypeptide comprising the fragment; a cell secreting the antibody or its portion; a pharmaceutical composition comprising the antibody; and methods of using the compositions for therapeutic, diagnostic and / or experimental purpose.

This invention provides a nucleotide analogue comprising (i) a base selected from the group consisting of adenine, guanine, cytosine, thymine and uracil, (ii) a deoxyribose, (iii) an allyl moiety bound to the 3′-oxygen of the deoxyribose and (iv) a fluorophore bound to the base via an allyl linker, and methods of nucleic acid sequencing employing the nucleotide analogue.

The invention belongs to the technical field of medicament, and particularly relates to preparation and application of phycocyanin extract. The phycocyanin extract is prepared by the following steps of: crushing spirulina cell walls of spirulina powder to obtain a crude extract by a repeated freeze-thawing method at the temperature of between 20 DEG C below zero and 4 DEG C; depositing the crude extract to obtain a crude protein extract by using 50 to 60 mass percent of ammonium sulfate; and then extracting and purifying the crude protein extract by adopting double aqueous phases, and removing salt by using excess infiltration to obtain phycocyanin extract solution. The phycocyanin extract mainly comprises phycocyanin, and the aqueous solution of the phycocyanin extract has the absorbance characteristics that A620 / 280 is slightly equal to 3.0+ / -0.2 and A620 / 650 is slightly equal to 2.2+ / -0.1. The phycocyanin extract is obtained by mainly combining the processes of ammonium sulfate deposition, double aqueous phase extraction, dialysis and salt removal and the like; and the phycocyanin extract administrated to S180 sarcoma mice with different dosages shows good tumor inhibiting effect and has no obvious toxicity on the spleen and the thymus gland.

The invention relates to a method for obtaining thymosins and / or the pharmaceutically acceptable salts thereof by means of solid-phase synthesis on polymeric supports, which comprises the steps of linearly synthesizing the thymus-derived peptides in solid phase, incorporating at least one Thr or Ser in the sequence, in pseudoproline dipeptide form, obtaining the thymosins by treating the peptidyl resin with trifluoroacetic acid, and purifying the thymosins by RP-HPLC. The present invention also protects the isolated and / or purified compound obtained by means of said method and also the use thereof in the preparation of a medicinal product.

The present disclosure provides methods for preventing or treating illness, improving responsiveness to immunization, and improving the efficacy of gene therapy in a patient by disrupting sex steroid signalling in the patient, wherein the bone marrow and other immune cell functionality is improved without, prior to, or concurrently with, thymic regeneration. In some embodiments, sex steroid signalling is interrupted or ablated in the patient by the administration of LHRH agonists, LHRH antagonists, anti-LHRH receptor antibodies, anti-LHRH vaccines, anti-androgens, anti-estrogens, selective estrogen receptor modulators (SERMs), selective androgen receptor modulators (SARMs), selective progesterone response modulators (SPRMs), ERDs, aromatase inhibitors, or various combinations thereof.

A medicine combination has the function of resisting lung cancer. The combination is mixed with rhizoma paridis saponin and milk vetch root amylose according to the weight ratio of 3 to 1. The rhizoma paridis is extracted by alcohol and then the rhizoma paridis extract is obtained through gradient elutriation of macroporous absorption resin alcohol; the milk vetch root is extracted by water and then the protein is settled and removed to get the milk vetch root amylose; the two extracts are mixed and the medicine is made. The MTT activities experiment in vitro with the MTT method has proven that the medicine combination can obviously control the growth of various lung cancer cells such as LA795 lung adenocarcinoma cell and the IC50 can reach 26.73 ug / ml; the experiment of mouse with the lung cancer tumor has represented that the tumor constraint rate can reach 55.63 percent; in this way, lung transfer of hypodermic transplanted tumor of the mouse with the lung cancer tumor can be obviously controlled and the tumor cells can be brought to death; moreover, spleen index and thymus index can be promoted and the medicine is innocuous and has no side effect. In addition, compared with the raw materials, the medicine combination has high activity and clear function; moreover, the medicine can be made into different types.

The invention belongs to the field of polypeptide synthesis, and relates to a method for preparing thymalfasin through dipeptide fragment liquid-solid bonding. By means of a liquid phase mode, a dipeptide fragment of continuous amino acid is synthesized, the dipeptide fragment is used for batch charging solid phase synthesis, and the problems that loci are difficult to couple, and a deletion peptide is prone to generation are solved. Meanwhile, purity and yield of crude peptides are increased. The technology is used for preparing the thymalfasin so that the purity of the crude peptides can be over 75%. Compared with the prior art, a synthetic route is simple, the problems that the difficult loci are not easy to couple and the deletion peptide is prone to generation are mainly solved, synthesis cost and purification cost are reduced, and industrial large-scale production is facilitated.

The present invention exploits the discovery that amounts of uracil and thymine metabolites, especially β-aminoisobutyric acid, in various bodily fluids, especially urine, are correlated with the occurrence of epilepsy when compared to matched control subjects. Analytical and diagnostic protocols, including a novel high performance liquid chromatography system, for use in the invention are disclosed.

Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×106 human Hep3B cells, followed by administration of two daily intraperitoneal doses of 0.5 mg / gram leptin for 6 weeks. Leptin administration induced a significant reduction in tumor size and improved survival in nude mice. Histologically, tumors of leptin-administered mice featured increased inflammatory exudate in interphase areas. Leptin-induced tumor suppression was associated with a significant increase in peripheral natural killer (NK) cell number. Splenocytes from leptin-treated mice featured decreased expression of CIS mRNA. To determine which lymphocyte subset is a prerequisite for the anti tumor effect of leptin, T&B cell deficient (Scid) mice and T,B& NK deficient (Scid-Beige) mice were subcutaneously implanted with Hep3B tumor cells, with and without the daily intraperitoneal administration of 0.5 mg / gram leptin for 6 weeks. SCID mice featured leptin-associated tumor suppression similar to those of nude mice. In contrast, NK-deficient SCID-Beige mice developed larger tumors. To further establish natural killer cell's central role in mediation of leptin's anti-tumor effect, NK cells were incubated in vitro with increasing doses of leptin, demonstrating a dose-dependent increase in cytotoxic activity. Incubation of leptin with hepatoma cell line was found to induce a dose-dependent reduction in hepatoma cell proliferation, suggesting an additive direct anti-tumor effect. Further synergism in inhibition of hepatoma cell proliferation in vitro was achieved following addition of natural killer cells. HCC cells expressed leptin receptor mRNA, while addition of leptin induced increased mRMA expression of STAT2 and SOCS1 on tumor cell lines. Leptin administration induces a significant suppression of human HCC. This effect is mediated by induction of natural killer cell proliferation and activation, and by direct inhibition of tumor growth. Decreased natural killer cell expression of inhibitory CIS protein and over expression of the anti-proliferative STAT2 and SOCS1 proteins in HCC lines may underline both anti cancerous effects of leptin.

The invention relates to the technical field of antibodies, and especially relates to a human thymus stromal lymphopoietin monoclonal antibody and an application thereof. The TSLP antibody can be specifically combined with hTSLP, has high affinity, and can effectively inhibit the combination of TSLP and a receptor thereof so as to inhibit activation of a downstream signal path and activation of immune cells by TSLP. The TSLP antibody has great significance in detection of the content of hTSLP and allergic asthma, and diagnosis, treatment and prognosis of inflammatory or allergic inflammatory diseases such as chronic obstructive pulmonary disease, allergic dermatitis, allergic rhinitis, allergic nasosinusitis, eosinophilic granulocytic esophagitis, allergic conjunctivitis, inflammatory bowel disease or atopic dermatitis.

The invention relates to the field of Chinese medicine, and in particular discloses a Chinese medicinal composition for enhancing immunity or delaying senility. The medicinal composition comprise the following raw materials in part by weight: 40 to 80 parts of astragalus, 10 to 25 parts of ginseng, 10 to 30 parts of medlar, 10 to 30 parts of glossy privet fruit, 10 to 30 parts of common yam rhizome, 10 to 30 parts of Indian buead, 10 to 25 parts of epimedium herb, 10 to 25 parts of mulberry, 5 to 20 parts of yerbadetajo herb, 10 to 25 parts of lucid ganoderma, 10 to 25 parts of tangerine peel and 5 to 20 parts of liquoric root. The Chinese medicinal composition can increase weights of immune organs of mice such as thymus and spleen, enhance the cellular immunity and ensure a dose-response relationship between the effect and the dosage, and can remarkably prolong the swimming time of the mice and keep the anti-fatigue effect in the dose-response relationship. The invention also provides a method for preparing the Chinese medicinal composition. The Chinese medicinal composition is a pure Chinese preparation, can enhance the resistance and delay the senility, and has the anti-fatigue effect and good application prospect.

The invention discloses lymphocyte antigen epitope peptides and application thereof, belongs to the fields of medical immunology and infectious diseases, and particularly relates to 164 thymus dependent lymphocyte antigen epitope peptides of five proteins of SARS-CoV-2 and application thereof. The antigen epitope peptides can be presented by HLA-A molecules to stimulate activation, proliferation and differentiation of SARS-CoV-2 specific thymus dependent lymphocytes, so that the immune effect of resisting SARS-CoV-2 infection is exerted. The antigen peptides can be used for preparing mixed polypeptide vaccines of SARS-CoV-2, recombinant protein vaccines connected with a plurality of epitope peptides in series and DNA and RNA vaccines, can be used for preparing a detection kit for detecting SARS-CoV-2 specific thymus dependent lymphocytes, can also be used for preparing effector thymus dependent lymphocytes or drugs for treating SARS-CoV-2 infection, and have a potential application value in the prevention, treatment and diagnosis of SARS-CoV-2 infection and COVID-19.

The invention discloses a thymopeptide-5 powder preparation and a preparation method thereof. The method comprises the following steps: dissolving excipient in water to produce solution I, and filtering the solution I to collect filtrate I; adding the thymopeptide-5 to the filtrate I to obtain solution II, and filtering solution II to collect filtrate II; and freezing and drying the filtrate II to obtain the thymopeptide-5 powder preparation. The excipient can be any one of mannite, lactose and glycin. Experiments prove that, in the thymopeptide-5 powder preparation, thymopeptide-5 is not easy to be degraded, and has good solubility; low content of 'related substances' which is below 1.0 percent, so that healing efficacy and safety of the thymopeptide-5 powder preparation can be greatly improved.

The invention provides a thymalfasin sustained-release microsphere preparation and a preparation method thereof. The thymalfasin sustained-release microsphere preparation comprises the following components in percentage by weight: 0.1 to 10 percent of thymalfasin, and 85 to 99 percent of poly(glycolide-co-lactide), wherein the poly(glycolide-co-lactide) is copolymer of glycolide and lactide, the ratio of the glycolide to the lactide is (25:75)-(75:25), the molecular weight of the poly(glycolide-co-lactide) is between 5,000 and 35,000 dalton, and the intrinsic viscosity is between 0.1 and 0.5dL / g. The pH value of the external water phase of the thymalfasin sustained-release microsphere preparation is between 3.0 and 5.0, and can be regulated by adopting acetic acid, hydrochloric acid, sulfuric acid and the like. The inventor discovers that by controlling the pH value of the external water phase, the stability of the thymalfasin can be improved and the entrapment rate in a preparation process also can be improved, so that the drug-loading rate of sustained-release microspheres can be improved.

The present invention describes compositions of thymus derived peptides and uses therefore in diagnostic methods and for the treatment of diseases associated with reduced T helper cell counts, diseases such as infection, e.g., HIV infection and other viral infections, parasitic, and bacterial infection, AIDS, ARC, multiple sclerosis, chronic fatigue syndrome, rheumatoid arthritis, Alzheimer's disease, asthma, allergy, dermatitis, type 1 diabetes mellitus, colitis, inflammatory bowel disease / irritable bowel syndrome, Crohn's disease, Psoriasis, Chronic obstructive pulmonary disease, Systemic lupus erythematosus, transplant rejection and cancer.

The invention relates to a composition of thymic peptide alpha 1 and thymopeptide-5 and a preparation method thereof. The compound preparation can be used for the treatment of chronic hepatitis B andvarious diseases with damaged immunological functions and the auxiliary treatment of tumours. The composition mainly comprises 0.1-10mg of thymic peptide alpha 1 and 0.1-100mg of thymopeptide-5. Simultaneously, proper auxiliary materials are added into the composition to prepare injection liquid or a freeze-drying medicament form. The composition prepared according to the proportion has obvious synergy action and can reach a better curative effect dose ratio for the treatment of the chronic hepatitis B and various diseases with damaged immunological functions and the auxiliary treatment of thetumours.

The invention discloses a medicament for treating geriatric disease, and at the medicament can be used for solving the technical problems of improving the functions of viscera, improving the immunity, invigorating qi and blood, and ensuring not to cause the body of middle-aged and aged people aiming at the geriatric disease. The technical scheme adopted by the invention is as follows: the medicament is characterized by comprising 1 to 5,000g of ants, 1 to 3,000g of glssy ganoderma, and 1 to 500g of pearl. Compared with the prior art, the unique broad-spectrum and immunity dual immunomodulatory action of ants are sufficiently played, the degraded thymus gland is promoted to proliferate, the weight is increased, the lymphocytes in the cortical area are increased, the functions of immunity center are activated, the leucocytes and lysozymes in the blood are increased, and the phagocytosis is improved. The medicament has the functions of nourishing kidney, tonifying spleen and dredging abdomen, tranquilizing by nourishing the heart and promoting blood circulation to remove meridian obstruction, so that the body is restored to a normal metabolizing state to comprehensively treat the geriatric disease. Therefore, the medicament achieves the aims of preventing and treating geriatric disease, delaying aging, improving wisdom and strengthening body, and protecting bodies of middle-aged and aged people from being hurt.

The invention relates to the field of biological monitoring, and specifically relates to a secondary antibody probe for a sandwich immune reaction by using an amperometric immunosensor, wherein, the secondary antibody probe is composed of calf thymus DNA molecular chains and nanospheres adhering to the calf thymus DNA molecular chains, and the surfaces of the nanospheres are covered by enzyme labeled antibody proteins while magnetic nanometer particles, which are formed by depositing a layer of amorphous zirconia on the surfaces of nanometer ferriferrous oxide particles, are filled in the nanospheres. The secondary antibody probe provided in the invention is suitable for measurring concentration of antigens by a sandwich immune reaction employing an amperometric immunosensor, and has the advantages of wide linear range of detection and low detection limits.

The invention discloses a Chinese hamster ovary culture medium as well as a preparation method and application thereof. The culture medium comprises ascorbic acid, pyridoxine hydrochloride, vitamin B12, nicotinamide, riboflavin, thiamine chloride, choline chloride, folic acid, calcium pantothenate, sodium pyruvate, reduced glutathione, inositol, biotin, hypoxanthine, putrescine, lipoic acid, linoleic acid, thymine, glucose, HEPES (2-hydroxyethyl) buffer solution, dextran sulphate, Pluronic-F68, various amino acids and salts thereof and various inorganic salts. The culture medium has low cost, and the component does not contain animal origin ingredients, does not contain protein and has definite chemical ingredients. All ingredients are cooperated and blended, and the Chinese hamster ovary culture medium can satisfy the basic growth requirement of cells, and can effectively regulate, transfer and control the culture of cells so as to realize good high-density cell culture. Compared with the culture effect of the existing culture medium, the culture effect of culture medium disclosed in the invention is at least equivalent to even superior to the existing culture medium.

The invention relates to the technical field of medicament, in particular to inonotus obliquus extracellular and intracellular mixing crude polysaccharide with a function of strengthening immunity, which is extracted from a submerged fermentation product of medical fungus inonotus obliquus liquid. The method comprises the following steps: taking slant strain under an asepsis condition, and inoculating the slant strain into a plate filled with fresh comprehensive solid culture medium; pumping and filtering a secondary fermentation product through primary fermentation and secondary fermentation to obtain inonotus obliquus mycelium and fermentation supernatant; and preparing the inonotus obliquus extracellular and intracellular mixing crude polysaccharide through concentration and water extraction and alcohol precipitation. In vivo experiments prove that the inonotus obliquus extracellular and intracellular mixing crude polysaccharide can prolong the surviving time of mice hepatocellular carcinoma H22 and S180 ascites tumor mice, and can obviously improve the thymus gland index and spleen index of the mice. Furthermore, the inonotus obliquus extracellular and intracellular mixing crude polysaccharide can obviously improve secretion of IL-2, TNF-alpha cell factors in the blood serum of the tumor-bearing mice, and can be used for preparing new immunity intensifying preparation. The invention opens up a new way for development and utilization of medical fungus resources.

The invention provides a kit for detecting human immune ages and an application of the kit. Reagents in the kit comprise CD3, CD4, CD31 and CD45RA monoclonal antibodies which are four fluoresceins applicable to flow cytometers, and the colors of the four fluoresceins are different. The reagents in the kit comprise, in weight percent, 0.66-94.34% of fluorescent labeled CD3, 0.66-94.34% of fluorescent labeled CD4, 0.66-94.34% of fluorescent labeled CD31 and 0.66-94.34% of fluorescent labeled CD345RA. The kit is used for detecting recently outputted cell number of human thymuses, the immune agesof people are determined according to detection results of the recently outputted cell number of the human thymuses, and the immune ability of a human body is evaluated.

A method of treating hypoparathyroidism in a human DiGeorge syndrome subject comprises (a) implanting thymus tissue into the subject in an amount effective to treat the DiGeorge syndrome; and (b) implanting, preferably concurrently implanting, parathyroid tissue into the subject in an amount effective to treat the hypoparathyroidism.

The invention discloses a method for extracting and synthesizing thymus microcapsule sustained release needle by PLGA which comprises the following steps, (1) carrying out thymolysis in small amount of water, obtaining inner layer water phase, (2) dissolving the PLGA into organic solution, obtaining organic phase, (3) dispersing the inner layer aqueous phase into organic phase during high-speed agitating, obtaining water-in-oil type emulsion (emulsion 1), (4) charging emulsion 1 into outer layer aqueous phase containing dispersing agent, agitating to form double layer emulsion, obtaining water / oil / water composite emulsion, (5) volatilizing the organic solvent and curing the polymeric layer, forming solid microsphere, thus coating the thymus gland at the center of the microsphere.

The invention discloses an anti-radiation traditional Chinese medicine composition which comprises the following components in parts by weight: 160-200 parts of membranous milkvetch root, 110-130 parts of scurfy pea, 80-100 parts of Chinese angelica, 160-200 parts of epimedium, 135-165 parts of madder root, 110-130 parts of glossy privet fruit, 110-130 parts of white paeony root, 110-130 parts ofradix rehmanniae preparata, 80-100 parts of Szechuan lovage rhizome, 215-265 parts of Chinese yam and 35-45 parts of prepared liquoric root. The traditional Chinese medicine composition can increase thymus index and spleen index of a 60Co gamma-radiated mouse and protect immune organs; improve the activity of superoxide dismutase in blood serum and the liver of the 60Co gamma-radiated mouse, reduce the content of malonaldehyde and improve the anti-oxidation capability of an organism; increase peripheral white blood cells of the 60Co gamma-radiated mouse and improve the hematogenesis function;and reduce the micronuclear rate of marrow cells of the 60Co gamma-radiated mouse and inhibit the action of causing chromosomal aberration of 60Co gamma rays. In addition, the traditional Chinese medicine composition is low in toxicity and side effects, and medicinal materials in the formula are low in price and easy to obtain, thereby having great development and application prospects in the aspects of preventing and treating radiation injuries.

The present invention discloses a canine TSLP protein and a nucleic acid that encodes that protein. Peptide fragments of the protein that comprise specific epitopes of the canine TSLP protein are also disclosed. The canine TSLP protein and related peptide fragments may be used as an antigen for immunological assays, as well as for vaccines that induce anti-TSLP antibodies. The present invention further discloses methods of making and using the canine TSLP gene, the canine TSLP protein, and the related peptide fragments.

The invention discloses a mesenchymal stem cell and the application thereof in resisting HIV-1 (human immunodeficiency virus), and particularly relates to a mesenchymal stem cell of a secreted-expression high-concentration keratinocyte growth factor (KGF), and the mesenchymal stem cell is produced through a micro-carrier culturing system. According to the invention, the mesenchymal stem cell can be used for promoting the development of the thymus gland, maintaining the functions of the thymus gland, and enhancing the immunologic function of specific T cells through increasing the output of T lymphocytes to peripheral blood, thereby achieving an effect of treating HIV-1 infection, and providing an effective new strategy for the clinical treatment of the acquired immunodeficiency syndrome.